Современные лазерные технологии в лечении урогенитальных расстройств у женщин


DOI: https://dx.doi.org/10.18565/pharmateca.2020.6.105-112

О.А. Пустотина

Академия медицинского образования им. Ф.И. Иноземцева, Санкт-Петербург, Россия
Урогенитальные расстройства встречаются у большинства женщин постменопаузального возраста. В данном обзоре представлены клинические и гистологические эффекты микроаблационного СО2-лазера и неаблационного эрбиевого лазера у женщин с вульвовагинальной атрофией, стрессовым недержанием мочи и пролапсом тазовых органов.
Ключевые слова: вульвовагинальная атрофия, недержание мочи, пролапс тазовых органов, СО2-лазер, эрбиевый лазер

Литература


1. Palacios S., Nappi R.E., Bruyniks N., et al. The European .Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018;21(3):286–91. Doi: 10.1080/13697137.2018.1446930.


2. Portman D.J., Gass M.L., Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North Am. Menopause Soc Menopause. 2014;21:1063. Doi: 10.1097/GME.0000000000000329.


3. Palacios S., Castelo-Branco C., Currie H., et al. Update on management of genitourinary syndrome of menopause: A practical guide. Maturitas. 2015;82:308–13. Doi: 10.1016/j.maturitas.2015.07.020.


4. Cagnacci A., Carbone M.M., Palma F. AGATA Study. Prevalence and association between objective signs and subjective symptoms of vaginal atrophy: the AGATA study. Menopause. 2016;23:1139–45. Doi: 10.1097/GME.0000000000000675.


5. Nappi R.E., Martini E., Cucinella L., et al. Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women. Front Endocrinol. 2019;10:561. Doi: 10.3389/fendo.2019.00561.


6. Panay N., Palacios S., Bruyniks N., et al. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas. 2019;124:55–61. Doi: 10.1016/j.maturitas.2019.03.013.


7. Prairie B.A., Klein-Patel M., Lee M., et al. What midlife women want from gynecologists: a survey of patients in specialty and private practices. J Womens Health. 2014;23:513–18. Doi: 10.1089/jwh.2013.4263.


8. Baber R.J., Panay N., Fenton A. the IMS Writing Group. IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–50. Doi: 10.3109/13697137.2015.1129166.


9. Archer D.F., Kimble T.D., Lin F.D.Y., et al. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0,003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom. J Womens Health (Larchmt). 2018;27(3):231–37. Doi: 10.1089/jwh.2017.6515.


10. Lethaby A., Ayeleke R.O., Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;(8):CD001500. Doi: 10.1002/14651858.


11. Bruyniks N., Biglia N., Palacios S., Mueck A.O. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric. 2017;20:195–204. Doi: 10.1080/13697137.2017.1284780.


12. Labrie F., Bélanger A., Pelletier G., et al. Science of intracrinology in postmenopausal women. Menopause. 2017;24(6):702–12. Doi: 10.1097/GME.0000000000000808.


13. Melisko M.E., Goldman M.E., Hwang J., et al. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA. Oncol. 2017;3(3):313–19. Doi: 10.1001/jamaoncol.2016.3904.


14. FSRH Guideline. Combined Hormonal Contraception, 2019// www.fsrh.org.uk.


15. Mitchell C.M., Reed S.D., Diem S., et al. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial. JAMA. Intern Med. 2018;178(5):681–90. Doi: 10.1001/jamainternmed.2018.0116.


16. Chatsiproios D., Schmidts-Winkler I.M., Konig L., et al. Topical treatment of vaginal dryness with a non-hormonal cream in women undergoing breast cancer treatment – An open prospective multicenter study. PLoS One. 2019;14(1):e0210967. Doi: 10.1371/journal.pone.0210967.


17. Arunkalaivanan A., Kaur H., Onuma O. Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence. Int Urogynecol J. 2017;28(5):681–85. Doi: 10.1007/s00192-017-3282-y.


18. Tadir Y., Gaspar A., Lev-Sagie A., et al. Light and Energy Based Therapeutics for Genitourinary Syndrome of Menopause: Consensus and Controversies. Lasers Surg Med. 2017;49:137–59. Doi: 10.1002/lsm.22637.


19. Gambacciani M., Palacios S. Laser therapy for the restoration of vaginal function. Maturitas. 2017;99:10–5. Doi: 10.1016/j.maturitas.2017.01.012.


20. Vizintin Z., Lukac M., Kazic M., Tettamanti M.Erbium laser in gynecology. Climacteric. 2015;18(Suppl. 1):4–8. Doi: 10.3109/13697137.2015.1078668.


21. Fisher J.C. Photons, physiatrics, and physicians: A practical guide to understanding laser light interaction with living tissue, part 1. J Clin Laser Med Surg. 1992;10(6):419–26.


22. Alexiades M.R. Wave science in dermatologic therapy. J Drugs Dermatol. 2015;14(11):1190.


23. Niemz M.H. Laser-tissue Interactions: Fundamentals and Applications (Biological and Medical Physics, Biomedical Engineering). Berlin, Heidelberg: Springer-Verlag, 2007.


24. Alexiades-Armenakas M.R., Dover J.S., Arndt K.A. Fractional laser skin resurfacing. J Drugs Dermatol. 2012;11(11):1274–87.


25. Prignano F., Campolmi P., Bonan P., et al. Fractional CO2 laser: A novel therapeutic device upon photobiomodulation of tissue remodeling and cytokine pathway of tissue repair. Dermatol Ther. 2009;22(Suppl. 1):S8–15. Doi: 10.1111/j.1529-8019.2009.01265.x.


26. Orringer J.S., Kang S., Johnson T.J., et al. Connective tissue remodeling induced by carbon dioxide laser resurfacing of photodamaged human skin. Arch Dermatol. 2004;140(11):1326–32. Doi: 10.1001/archderm.140.11.1326.


27. Manolis E.N., Kaklamanos I.G., Spanakis N., et al. Tissue concentration of transforming growth factor b1 and basic fibroblast growth factor in skin wounds created with a CO2 laser and scalpel: A comparative experimental study, using an animal model of skin resurfacing. Wound Repair Regen. 2007;15:252–57.


28. Dams S.D., de Liefde-van Beest M., Nuijs A.M., et al. Pulsed Heat shocks enhance procollagen type I and procollagen type III expression in human dermal fibroblasts. Skin Res Technol. 2010;16(3):354–64. Doi: 10.1111/j.1600-0846.2010.00441.x.


29. Salvatore S., Leone Roberti Maggiore U., Athanasiou S., et al. Histological study on the effect of microablative fractional CO2 laser on atrophic vaginal tissue: An ex vivo study. Menopause. 2015;22(8):845–49.


30. Zerbinati N., Serati M., Origoni M., et al. Microscopic and ultrastructural modifications of postmenopausal atrophis vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci. 2015;30(1):429–36. Doi: 10.1007/s10103-014-1677-2.


31. Gaspar A., Addamo G., Brandi H. Vaginal Fractional CO2 Laser: A Minimally Invasive Option for Vaginal Rejuvenation. Am J Cosmet Surg. 2011;28:156–62.


32. Lee M.S. Treatment of vaginal relaxation syndrome with an Erbium:YAG laser using 90° and 360° scanning scopes: A pilot study & short-term results. Laser Ther. 2014;23(2):129–38. Doi: 10.5978/islsm.14-OR-11.


33. Vizintin Z., Rivera M., Fistonić I., et al. Novel Minimally Invasive VSP Er: YAG Laser Treatments in Gynecology. J LAHA. 2012;1;46–58.


34. Gaspar A., Brandi H., Gomez V., Luque D. Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Lasers Surg Med. 2017;49(2):160–8. Doi: 10.1002/lsm.22569.


35. Gambacciani M., Levancini M. Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. Menopause. 2017;24(3):316–19. Doi: 10.1097/GME.0000000000000761.


36. Athanasiou S., Pitsouni E., Antonopoulou S.,et al. The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women. Climacteric. 2016;19(5):512–18. Doi: 10.1080/13697137.2016.1212006.


37. Salvatore S., Nappi R.E., Zerbinati N., et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: A pilot study. Climacteric. 2014;17(4):363–69. Doi: 10.3109/13697137.2014.899347.


38. Sokol E.R., Karram M. An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause. 2016;23(10):1102–107. Doi: 10.1097/GME.0000000000000700.


39. Pieralli A., Fallani M.G., Becorpi A., et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet. 2016;294(4):841–46. Doi: 10.1007/s00404-016-4118-6.


40. Pitsouni E., Grigoriadis T., Tsiveleka A., et al. Microablative fractional CO2-laser therapy and the genitourinary syndrome of menopause: An. Observational. study. Maturitas. 2016;94:131–36. Doi: 10.1016/j.maturitas.2016.09.012.


41. Isaza P.G., Jaguszewska K., Cardona J.L., Lukaszuk M.Long-term effect of thermoablative fractional CO2 laser treatment as a novel approach to urinary incontinence management in women with genitourinary syndrome of menopause. Int Urogynecol J. 2018;29:211–15. Doi: 10.1007/s00192-017-3352-1.


42. Patel F. The effects of RF excited fractional CO2 laser on the vaginal canal in treating stress urinary incontinence


43. Salvatore S., Nappi R.E., Parma M., et al. Sexual function after fractional microablative CO2laser in women with vulvovaginal atrophy. Climacteric. 2015;18:219–25.


44. Beltram M., Drnovsek-Olup B. Histological and biomolecular analysis of new collagen synthesis after «smooth» mode Er:YAG laser skin resurfacing. Lasers Surg Med. 2004;1(16):56.


45. Lukac M., Perhavec T., Nemes K., Ahcan U. Ablation and thermal depths in VSP Er: YAG laser skin resurfacing. J LAHA. 2010;1:56–71.


46. MEC software is available in Dynamis laser family developed by Fotona d.d. www.fotona.com.


47. Gambacciani M., Levancini M. Short-term effect of vaginal erbium laser on the genitourinary syndrome of menopause. Minerva Ginecol. 2015;67(2):97–102.


48. Gambacciani M., Levancini M., Cervigni M. Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause. Climacteric.2015;18:757–63. Doi: 10.3109/13697137.2015.1045485.


49. Gambacciani M., Levancini M., Russo E., et al. Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. Climacteric. 2018;21(2):148–52. Doi: 10.1080/13697137.2018.1436538.


50. Gambacciani M., Torelli M.G., Martella L., et al. Rationale and design for the vaginal erbium laser academy study (VELAS): an international multicenter observational study on genito- urinary syndrome of menopause and stress urinary incontinence. Climacteric. 2015;18(Suppl. 1):43–8.


51. Haylen B.T., Maher C.F., Barber M.D., et al. An International Urogynecological Association (IUGA)/ International Continence Society (ICS) joint report on the terminology for female pelvic organ prolapse (POP). Int Urogynecol J. 2016;27(2):165–94. Doi: 10.1007/s00192-015-2932-1.


52. Miranne J., Marek T.M., Mete M., Iglesia C.B. Prevalence and resolution of auditory passage of vaginal air in women with pelvic floor disorders. Obstet Gynecol. 2015;126(1):136–43. Doi: 10.1097/AOG.0000000000000921.


53. Friedman T., Eslick G.D., Dietz H.P. Risk factors for prolapse recurrence: systematic review and meta-analysis. Int Urogynecol J. 2018;29:13–21. Doi: 10.1007/s00192-017-3475-4.


54. Iglesia C.B., Yurteri-Kaplan L., Alinsod R. Female genital cosmetic surgery: A review of techniques and outcomes. Int Urogynecol J. 2013;24(12):1997–2009. Doi: 10.1007/s00192-013-2117-8.


55. Gaviria J.E., Korosec B., Fernandez J., Montero G.J.Up to 3-year follow-up of patients with vaginal relaxation syndrome participating in laser vaginal tightening. J. Laser Health Acad. 2016;2016(1):6–11.


56. De Landsheere L., Munaut C., Nusgens B., et al. Histology of the vaginal wall in women with pelvic organ prolapse: A literature review. Int Urogynecol J. 2013;24(12):2011–20. Doi: 10.1007/s00192-013-2111-1.


57. Vergeldt T.F., Weemhoff M., IntHout J., Kluivers K.B. Risk factors for pelvic organ prolapse and its recurrence: a systematic review. Int Urogynecol J. 2015;26:1559–73. Doi: 10.1007/s00192-015-2695-8.


58. Jelovsek J.E., Maher C., Barber M.D. Pelvic organ prolapse. Lancet. 2007;369:1027–38.


59. Bump R.C., Mattiasson A., B.K., et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol. 1996;175:10–7. Doi: 10.1016/s0002-9378(96)70243-0


60. Novi J.M., Jeronis S., Morgan M.A., Arya L.A. Sexual function in women with pelvic organ prolapse compared to women without pelvic organ prolapse. J Urol. 2005;173:1669–72. Doi: 10.1097/01.ju.0000154618.40300.c8.


61. Hendrix S.L., Clark A., Nygaard I., et al. Pelvic organ prolapse in the Women’s Health Initiative: gravity and gravidity. Am J Obstet Gynecol. 2002;186:1160–66. Doi: 10.1067/mob.2002.123819.


62. Samuelsson E.C., Victor F.T., Tibblin G., Svärdsudd K.F. Signs of genital prolapse in a Swedish population of women 20 to 59 years of age and possible related factors. Am J Obstet Gynecol. 1999;180:299–305. Doi: 10.1016/s0002-9378(99)70203-6.


63. Dallas K., Elliott C.S., Syan R., et al. Association Between Concomitant Hysterectomy and Repeat Surgery for Pelvic Organ Prolapse Repair in a Cohort of Nearly 100,000 Women. Obstet Gynecol. 2018;132:1328–36. Doi: 10.1097/AOG.0000000000002913.


64. Lavelle R.S., Christie A.L., Alhalabi F., Zimmern P.E.Risk of Prolapse Recurrence after Native Tissue Anterior Vaginal Suspension Procedure with Intermediate to Long-Term Follow up. J Urol. 2016;195:1014–20. Doi: 10.1016/j.juro.2015.10.138.


65. Lazarou G., Minis E., Grigorescu B. Outcomes of stress urinary incontinence in women undergoing TOT versus Burch colposuspension with abdominal sacrocolpopexy. Int Urogynecol J. 2019;30:245–50. Doi: 10.1007/s00192-018-3668-5.


66. Blaivas J.G., Purohit R.S., Benedon M.S., et al. Safety considerations for synthetic sling surgery. Nat Rev Urol. 2015;12:481–509. Doi: 10.1038/nrurol.2015.183.


67. Olsson I., Abrahamsson A.K., Kroon U.B. Long-term efficacy of the tension-free vaginal tape procedure for the treatment of urinary incontinence: A retrospective follow-up 11,5 years post-operatively. Int. Urogynecol. J Pelvic Floor Dysfunct. 2010;21:679–83. Doi: 10.1007/s00192-009-1083-7.


68. Culligan P.J. Nonsurgical management of pelvic organ prolapse. Obstet Gynecol. 2012;119:852–60. Doi: 10.1097/AOG.0b013e31824c0806.


69. Mannela P., Palla G., Bellini M., Simoncini T. The female pelvic floor through midlife and aging. Maturitas. 2013;76(2):30–4. Doi: 10.1016/j.maturitas.2013.08.008.


70. Tinelli A., Malvasi A., Rahimi S., et al. Age-related pelvic floor modifications and prolapse risk factors in postmenopausal women. Menopause. 2010;17:204–12. Doi: 10.1097/gme.0b013e3181b0c2ae.


71. Han L., Wang L., Wang Q., et al. Assotiation between pelvic organ prolapse and stress urinary incontinence with collagen. Exp Ther Med. 2014;7:1337–41. Doi: 10.3892/etm.2014.1563.


72. Fistonić N., Fistonić I., Lukanovic A., et al. First assessment of short-term efficacy of Er:YAG laser treatment on stress urinary incontinence in women: prospective cohort study. Climacteric. 2015;18:37–42. Doi: 10.3109/13697137.2015.1071126.


73. Ogrinc U.B., Sencar S., Lenasi H. Novel minimally invasive laser treatment of urinary incontinence in women. Lasers Surg Med. 2015;47(9):689–97. Doi: 10.1002/lsm.22416


74. Pardo J.I., Sola V.R., Morales A.A. Treatment of female stress urinary incontinence with erbium- YAG laser in non-ablative mode. Eur J Obstet Gynecol Reprod Biol. 2016;204:1–4. Doi: 10.1016/j.ejogrb.2016.06.031.


75. Fistonic N., Fistonic I., Findri-Gustek S., et al. Minimally invasive, non-ablative Er:YAG laser treatment of stress urinary incontinence in womenь – a pilot study. Lasers Med Sci. 2016;31:635–43.


76. Tien Y.W., Hsiao S.M., Lee C.N., Lin H.H. Effects of laser procedure for female urodynamic stress incontinence on pad weight, urodynamics, and sexual function. Int Urogynecol J. 2017;28:469–76. Doi: 10.1007/s00192-016-3129-y.


77. Lapii G.A., Yakovleva A.Y., Neimark A.I. Structural reorganization of the vaginal mucosa in stress urinary incontinence under conditions of Er: YAG laser treatment. Bull Exp Biol Med. 2017;162:510–14. Doi: 10.1007/s10517-017-3650-0.


78. Ogrinc U.B., Sencar S. Non-ablative vaginal erbium YAG laser for the treatment of cystocele. Ital J Gynaecol Obstet. 2017;29(1):19–25.


79. Blaganje M., Scepanovic D., Zgur L., et al. Non-ablative Er:YAG laser therapy effect on stress urinary incontinence related to quality of life and sexual function: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2018;224:153–58. Doi: 10.1016/j.ejogrb.2018.03.038.


80. Perino A., Cucinella G., Gugliotta G., et al. Is vaginal fractional CO2 laser treatment effective in improving overactive bladder symptoms in post- menopausal patients? Preliminary results. Eur Rev Med Pharmacol Sci. 2016;20:2491–97.


81. Fistonić I., Fistonić N. Baseline ICIQ-UI score, body mass index, age, average birth weight, and perineometry duration as promising predictors of the short-term efficacy of Er:YAG laser treatment in stress urinary incontinent women: a prospective cohort study. Lasers Surg Med. 2018;50:636–43. Doi: 10.1002/lsm.22789.


82. Lane T.M., Shah P.J.R. Valsalva leak point pressure in the evaluation of stress urinary incontinence. Braz J Urol. 2000;26:420–25.


83. Gaspar A., Brandi H. Non-ablative erbium YAG laser for the treatment of type III stress urinary incontinence (intrinsic sphincter deficiency). Lasers Med Sci. 2017;32:685–91. Doi: 10.1007/s10103-017-2170-5.


84. Gaspar A., Maestri S., Silva J., et al. Intraurethral erbium: YAG laser for the management of urinary symptoms of genitourinary syndrome of menopause: a pilot study. Lasers Surg Med. 2018;50:802–7. Doi: 10.1002/lsm.22826.


85. Mitrofanoff L., Sikorski P. CASE REPORT: Successful Intra-anal Non-ablative Er:YAG Laser Treatment for the Symptoms of Rectal Prolapse. J Laser Health Acad. 2019;1.


86. Gambacciani M. Laser Treatment for Vulvovaginal Atrophy in book “Postmenopausal Diseases and Disorders” Ed. F.R. Pérez-López. 2019. P. 205–10.


87. Fistonic I., Fistonic N. Laser treatment in female urinary incontinence. in book “Postmenopausal Diseases and Disorders” Ed. F.R. Pérez-López. 2019. P. 211–24.


Об авторах / Для корреспонденции


Автор для связи: О.А. Пустотина, д.м.н., профессор кафедры акушерства и гинекологии с курсом репродуктивной медицины, Академия медицинского образования им. Ф.И. Иноземцева, Санкт-Петербург, Россия; e-mail: pustotina@gmail.com; ORCID: https://orcid.org/0000-0001-6117-7270 
Адрес: 190013, Россия, Санкт-Петербург, Московский пр-т, 22, лит. М


Бионика Медиа